Change in fair 
 value of 
 derivative asset             -            -          (81)           - 
Other income 
 (expense), net              (3)         922           12          964 
                      ---------    ---------    ---------    --------- 
Loss before 
 provision for 
 income taxes            (5,732)      (4,912)     (15,260)     (16,934) 
Provision for 
income taxes                  -            -            -            - 
                      ---------    ---------    ---------    --------- 
Net loss 
 attributable to 
 Vaccinex, Inc. 
 common 
 stockholders        $   (5,732)  $   (4,912)  $  (15,260)  $  (16,934) 
                      =========    =========    =========    ========= 
Comprehensive loss   $   (5,732)  $   (4,912)  $  (15,260)  $  (16,934) 
                      =========    =========    =========    ========= 
Net loss per share 
 attributable to 
 Vaccinex, Inc. 
 common 
 stockholders, 
 basic and diluted   $    (2.83)  $   (15.25)  $    (8.85)  $   (59.95) 
                      =========    =========    =========    ========= 
Weighted-average 
 shares used in 
 computing net loss 
 per share 
 attributable to 
 Vaccinex, Inc. 
 common 
 stockholders, 
 basic and diluted    2,026,920      322,153    1,724,088      282,467 
                      =========    =========    =========    ========= 
 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/551b0bc4-4495-4a65-aa21-a96daddf079e

(END) Dow Jones Newswires

November 18, 2024 08:30 ET (13:30 GMT)